Enterprise Value

111.1M

Cash

340.1M

Avg Qtr Burn

N/A

Short % of Float

12.74%

Insider Ownership

4.88%

Institutional Own.

96.48%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zanidatamab (HER2) Details
Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas

Phase 3

Data readout

Zanidatamab (HER2) Details
Cancer, Solid tumor/s, Biliary Tract Cancer

Phase 2b

Data readout

Zanidatamab (HER2) + chemotherapy + tislelizumab Details
Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas

Phase 2

Update

Zanidatamab zovodotin (ZW49) Details
HER2-expressing cancers, Cancer, Non-small cell lung carcinoma

Phase 2

Update

Phase 1/2

Data readout